Skip to main content
OKYO
NASDAQ Life Sciences

Urcosimod 2a期试验显示在神经病性角膜痛中取得了有意义的生活质量改善

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$1.6
Mkt Cap
$82.192M
52W Low
$1.03
52W High
$3.349
Market data snapshot near publication time

summarizeSummary

OKYO Pharma宣布其药物候选物Urcosimod在治疗神经病性角膜痛（NCP）的新阳性探索性2a期数据。数据表明，患者报告的生活质量（QoL）结果（包括情感健康和日常生活满意度）相比安慰剂有了显著改善。这建立在同一小型2a期试验中先前报告的主要疗效信号（疼痛减轻）之上。NCP是一种严重的疾病，目前没有FDA批准的治疗方法，代表着一个重大的未满足的医疗需求。虽然数据来自一个小型试验（n=6每组）的探索性分析，但这些阳性的生活质量发现与疼痛减轻一起，表明Urcosimod具有更广泛的治疗特征，并加强了其推进的理由。该公司计划进行确认性研究，包括一个较大的多中心2b/3期试验，这将是验证这些鼓舞人心的初步结果的关键。

在该公告发布时，OKYO的交易价格为$1.60，交易所为NASDAQ，所属行业为Life Sciences，市值约为$8219.2万。 52周交易区间为$1.03至$3.35。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed OKYO - Latest Insights

OKYO
Apr 29, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
OKYO Pharma to Present Positive Phase 2 Urcosimod Data for Neuropathic Corneal Pain at Major Scientific Conferences
Sentiment: Positive
View Wiseek Article
OKYO
Apr 07, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
OKYO Pharma Advances Lead Candidate Urcosimod with Positive Phase 2 Data and Pivotal Trial Plans
Sentiment: Positive
View Wiseek Article
OKYO
Mar 18, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Urcosimod Phase 2a Trial Shows Meaningful QoL Improvements in Neuropathic Corneal Pain
Sentiment: Positive
View Wiseek Article
OKYO
Mar 12, 2026, 4:18 PM EDT
Filing Type: 6-K
Importance Score:
8
OKYO Pharma Secures Additional $2.05M from Over-Allotment, Bringing Total Offering Proceeds to $22M
Sentiment: Positive
View Wiseek Article
OKYO
Feb 23, 2026, 11:00 AM EST
Filing Type: 6-K
Importance Score:
9
OKYO Pharma's Urcosimod Shows Clinically Meaningful Pain Reduction in Phase 2a NCP Trial; Advances to Phase 2b/3
Sentiment: Positive
View Wiseek Article
OKYO
Feb 17, 2026, 8:23 AM EST
Filing Type: 424B5
Importance Score:
8
OKYO Pharma Finalizes $18.5M Public Offering, Issuing 10.8M Shares at $1.85
Sentiment: Negative
View Wiseek Article
OKYO
Feb 13, 2026, 6:06 AM EST
Filing Type: 6-K
Importance Score:
8
OKYO Pharma Prices $20M Public Offering at $1.85 Per Share, Significant Dilution Expected
Sentiment: Negative
View Wiseek Article
OKYO
Feb 12, 2026, 4:14 PM EST
Filing Type: 6-K
Importance Score:
8
OKYO Pharma Announces Intent for Underwritten Public Offering of Ordinary Shares
Sentiment: Negative
View Wiseek Article
OKYO
Feb 10, 2026, 8:26 PM EST
Filing Type: 6-K
Importance Score:
8
OKYO Pharma Establishes $50M At-The-Market Offering Program
Sentiment: Negative
View Wiseek Article
OKYO
Feb 10, 2026, 8:24 PM EST
Filing Type: 424B5
Importance Score:
9
OKYO Pharma Initiates Highly Dilutive $50M At-The-Market Offering to Fund Operations
Sentiment: Negative
View Wiseek Article